Table 4.
Results and adverse events within included studies for ablation.
| Investigators | Follow-up (mo) (range) | Technical success | Technical effectiveness | PFS (EG or EG vs CG) | Median OS (EG or EG vs CG) | Adverse events (grade III/IV) |
|---|---|---|---|---|---|---|
| Carrafiello (75) | Mean 17.5 (13–21) | / | 66 | / | / | None |
| Kim (76) | Median 19.5 (3.3–82.1) | 88% | 88% | 32.2 mo | 38.5 mo | Liver abscess (n = 1) |
| Giorgi (77) | Median 19.5 (9-64) | / | 66 | / | / | None |
| Yu (87) | Mean 12.8 (4–31) | 91.70% | 87.50% | / | 10 mo | Liver abscess (13.3%), needle seeding (6.7%) |
| Zhang (88) | Median 20.1 (2.8–63.5) | 100% | 93.00% | 8.9 mo (95% CI,6.5–11.3) | 28 mo (95% CI, 23.7–32.2) | Pleural effusion (1.9%), liver abscess (0.9%) |
| Xu (89) | / | 100 vs 100% | 100 vs 100% | P = 0.589 | 31.3 vs 29.4, P = 0.405 | MWA: hepatic failure (n = 1), liver abscesses (n = 2), ascites (n = 1) |
| SR: hepatic failure (n = 2), ascites (n = 6), jaundice (n = 3) | ||||||
| MWA vs SR: 5.3 vs 13.8% (P < 0.001) | ||||||
| Belfiore (98) | (6–48) | 100% | 100% | / | 18 mo (95% CI, 18.8–36.7) | None |
PFS, progression-free survival; OS, overall survival; MWA, microwave ablation; SR, surgical resection; CG, control group; EG, experimental group.